Psoriatic Arthritis.

  title={Psoriatic Arthritis.},
  author={Christopher T. Ritchlin and Robert A. Colbert and Dafna D. Gladman},
  journal={The New England journal of medicine},
  volume={376 10},
Psoriasis is a common skin disease that is associated with multiple coexisting conditions. The most prevalent coexisting condition, psoriatic arthritis, develops in up to 30% of patients with psoriasis and is characterized by diverse clinical features, often resulting in delayed diagnosis and treatment. Initial reports emphasized a benign course in most patients, but it is now recognized that psoriatic arthritis often leads to impaired function and a reduced quality of life.1,2 Fortunately… 

Figures and Tables from this paper

Psoriatic arthritis.

JAK Inhibitors Taking on Psoriatic Arthritis.

Several medications are used to treat psoriatic arthritis, and the choice of agent and the timing of administration in the course of the disease depend on disease manifestations, their severity, and prognostic factors.

Current concepts and unmet needs in psoriatic arthritis

Better identification of early disease and knowledge of prognostic markers would enable clinicians to initiate appropriate therapy with the expectation that early aggressive treatment will minimise joint damage progression.

Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?

There is a potential unmet need to redefine PsA because of the frequent association with extraarticular manifestations and comorbidities and the possibility of personalized medicine, with different phenotypes or biomarkers has also been proposed.

Role of diagnostic imaging in psoriatic arthritis: how, when, and why

The role of imaging modalities in diagnosis, follow-up and prognosis of PsA is described, with a focus on radiography and CT, which have emerged as helpful tools to evaluate magnitude and severity of active inflammatory lesions.

Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East

Psoriatic arthritis (PsA) is a chronic, inflammatory arthropathy occurring in up to 30% of patients with psoriasis, and is characterized by multiple manifestations including peripheral arthritis,

Psoriatic arthritis

With efforts underway aimed at improving the understanding of the molecular basis for the heterogeneity of PsA, a personalized approach to treating PsA may become possible and the challenges in diagnosis and advances in treatment are highlighted.

Psoriatic arthritis: the role of the nonphysician clinician in the diagnosis and treatment of patients with psoriasis

An overview of psoriasis and psoriatic arthritis is provided and the multiple treatment options that are available are discussed, including multiple biologic agents that inhibit specific cellular mediators of inflammation either directly or indirectly.

Biologic therapy of psoriatic arthritis.

Anti-TNF agents and anti-T cell agents have shown excellent responses in clinical variables, health related quality of life and function, and in preventing radiological progression in Psoriatic arthritis.

Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines.

The specific methods and procedures used in this evidence-based, systematic review of treatments for PsA are outlined and it is hoped that they will provide a basis for future treatment guidelines.


There is not a strong correlation between the severity of psoriasis and the development of arthritis, although psoriatic arthritis may be present more frequently in patients with Psoriasis attending dermatology clinics, compared to primary care.

The diagnosis and treatment of early psoriatic arthritis

Tumor necrosis factor antagonists can alleviate the signs and symptoms of established psoriatic arthritis and inhibit radiographic progression, but the therapeutic impact of early intervention with these agents requires further study.

Outcome measures in psoriatic arthritis

There is a great need for standardized outcome measures that can accurately assess the activity of disease and response to therapy in PsA, which is a heterogeneous and multifaceted condition.

Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need.

Patients with psoriasis represent a unique opportunity to identify individuals at very high risk of developing a chronic inflammatory arthropathy and by early identification of these patients, knowledge about PsA risk factors is especially important.

Recent Advances in Imaging in Psoriatic Arthritis

A review of the recent advances in imaging in PsA, focusing primarily on ultrasonography and magnetic resonance imaging of peripheral disease manifestations is presented.

Recognizing and managing comorbidities in psoriatic arthritis

All clinicians caring for patients with psoriatic arthritis should be aware of the relevant comorbidities affecting patients with PsA and should have an understanding of how these comorbbidities affect management.

Epidemiology of Psoriatic Arthritis

The challenges in conducting epidemiological studies in PsA neatly elucidated in 1994 by O’Neill and Silman are still relevant, and the most important problem identified was lack of validated classification criteria.

Patients with juvenile psoriatic arthritis comprise two distinct populations.

It is suggested that the presence of dactylitis, rather than age, has the greatest capacity to predict essential features of the clinical phenotype, and future studies should avoid the assumption that PsA in childhood constitutes a single etiologic entity.